Results 191 to 200 of about 8,071,482 (284)

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Regional variations in healthcare in people living with dementia in Germany: protocol for a mixed-methods study. [PDF]

BMJ Open
Scheibner HJ, Gesell D, Hauptmann M, Heinze M, Horenkamp-Sonntag D, Koller D, Kubat D, Marschall U, Meixner J, Michalowsky B, von Peter S, Platen M, Riederer C, Schroth J, Swart E, Weirauch L, Dahling V.   +16 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Postgraduate training in general practice in Germany: A narrative review. [PDF]

Ger Med Sci
Tornow C, Freyer Martins Pereira J, Mathias E, Chenot JF.   +3 more
europepmc   +1 more source

Low‐intervention clinical trials in Spain: Do they progress?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims Low‐Intervention Clinical Trials (LICTs) are generally pragmatic trials that investigate medicinal products already authorized for use. In 2014, simplified regulatory frameworks were introduced for LICTs with the aim of reducing regulatory burden and operational complexity, to foster non‐commercial clinical trials (NCCTs); the mandatory ...
Claudia Erika Delgado‐Espinoza, Mayro J. Cortés Pestana, Kristopher Amaro, Rosa M. Antonijoan, Caridad Pontes   +4 more
wiley   +1 more source

Social Medical Insurances, Choices of Medical Institutions and the 'Siphon Effect' in the Health Service Market: Evidence from 2021 Yangtze River Delta Region of China. [PDF]

Risk Manag Healthc Policy
Yang G, Zhang X, Xu Z, Zhang L.
europepmc   +1 more source

A New Outcomes-Based Payment Plan From a Chinese Company to Improve Patient Affordability of CAR-T Product. [PDF]

Int J Health Policy Manag
Zheng SL, Zhang XQ.
europepmc   +1 more source

Cannabinoids and drug–drug pharmacokinetic interactions: Deciphering the risks

British Journal of Clinical Pharmacology, EarlyView.
The relationship between cannabinoids and mental health has become a major focus of scientific inquiry and public discourse. Cannabinoids are diverse chemical compounds from the Cannabis species that have been explored for their therapeutic applications in treating chronic pain, psychiatric and neurological conditions, such as depression, schizophrenia,
Paraskevi Papakyriakopoulou, Georgia Valsami, Georgios Ismailos   +2 more
wiley   +1 more source

Determining the feasibility of linked claims and vaccination data for a COVID-19 vaccine pharmacoepidemiological study in Germany-RiCO feasibility study protocol. [PDF]

BMJ Open
Timmesfeld N, Ihle P, Denz R, Meiszl K, Scholz K, Oberle D, Drechsel-Bäuerle U, Keller-Stanislawski B, Diebner HH, Meyer I.   +9 more
europepmc   +1 more source